UiPath CEO Daniel Dines Sells 2.5M Shares for $33.1M Under 10b5-1 Plan
PATH sits 42% above its 52-week low of $9.2.
Summary
UiPath CEO and chairman Daniel Dines sold 2.5 million shares for $33.1 million under a pre-arranged 10b5-1 plan, a larger tranche than his August sale and part of a broader pattern of insider distribution.
Key Events · Ownership and Investor Activity · PATH
-
CEO Sells 2.5M Shares for $33.1M
Daniel Dines disposed of 2.5 million Class A shares across three transactions on 2026-10-15 and 2026-10-16 at prices ranging from $12.98 to $13.83.
-
Larger Than Prior Tranche
This sale is roughly 1.8x the ~1.4 million shares / $22.5 million he sold in August, indicating an accelerated pace within the same 10b5-1 program.
-
Remaining Stake 28.99M Shares
Post-transaction direct holdings are 28,991,238 shares; he remains CEO, chairman, director and a 10% owner.
-
Insider Distribution Pattern
90-day open-market insider activity shows $28.6M of net selling across five insiders with no open-market purchases, and this is the 11th Form 4 in 90 days.
Analysis · PATH · Technology
Dines sold 2.5 million shares over two days at $12.98-$13.83, roughly 1.8x the size of his August tranche, leaving him 28.99 million shares. The sale is pre-planned and mechanical, but it is the largest single tranche in a 90-day stretch that has seen $28.6M of net insider selling with zero open-market buys — a persistent supply overhang rather than a discretionary call on the business.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PATH was trading at $13.09 on NYSE in the Technology sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $9.20 to $19.84. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.